Investors and Media



Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins as novel therapeutics to treat unmet medical needs. We are worldwide leaders in developing zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification. Our ZFP technology platform has multiple applications in:

  • Human Therapeutics
  • High-value Research Tools
  • Transgenic Animals
  • Cell-line Engineering for Protein Manufacturing
  • Plant Agriculture

View all »   RSSRecent Releases

Mar 20, 2014
Sangamo BioSciences Announces Pricing Of Public Offering Of Common Stock

Mar 19, 2014
Sangamo BioSciences Announces Public Offering Of Common Stock


Stock Quote

Ticker:
SGMO
Exchange:
NASDAQ
Price:
14.24
Change:
- 0.02
Day High:
14.54
Day Low:
13.74
Volume:
642,900
11:31 AM ET on Apr 17, 2014

Shareholder Tools